✦ LIBER ✦

P1119 EARLY VIRAL KINETICS DO NOT PREDICT TREATMENT OUTCOME WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 24 WEEKS IN HCV GENOTYPE 2/3 PATIENTS IN THE VALENCE TRIAL

✍ Scribed by Zeuzem, S.; Dusheiko, G.M.; Colombo, M.; Flisiak, R.; Hyland, R.H.; Illeperuma, A.; Brainard, D.M.; Symonds, W.T.; McHutchison, J.G.; Weiland, O.; Reesink, H.W.; Brown, A.; Pol, S.; Hezode, C.; Esteban, R.

Book ID: 122228354
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 64 KB
Volume: 60
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(14)61279-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Su1064 Early Viral Kinetics Do Not Predi

Su1064 Early Viral Kinetics Do Not Predict Treatment Outcome With Sofosbuvir + Ribavirin for 12 or 24 Weeks in HCV Genotype 2/3 Patients in the Valence Trial

✍ Zeuzem, Stefan; Flisiak, Robert; Hyland, Rob H.; Illeperuma, Ari; Brainard, Dian 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 554 KB

[606] COMPARISON OF PEGINTERFERON a-2a A

[606] COMPARISON OF PEGINTERFERON a-2a AND RIBAVIRIN FOR 12 OR 24 WEEKS IN PATIENTS WITH HCV GENOTYPE 2/3: THE NORDYNAMIC TRIAL

✍ M. Lagging; C. Pedersen; M. Rauning Buhl; M. Farkkila; N. Langeland; K. Morch; G 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 144 KB

O109 ALL ORAL FIXED-DOSE COMBINATION SOF

O109 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-2 STUDY

✍ Afdhal, N.; Reddy, R.K.; Pockros, P.; Di Bisceglie, A.M.; Arora, S.; Yang, J.C.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 151 KB

O164 ALL ORAL FIXED-DOSE COMBINATION SOF

O164 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY

✍ Mangia, A.; Marcellin, P.; Kwo, P.; Foster, G.R.; Buti, M.; Bräu, N.; Muir, A.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Tu2038 All Oral Fixed-dose Combination S

Tu2038 All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study

✍ Jacobson, Ira M.; Marcellin, Patrick; Mangia, Alessandra; Kwo, Paul Y.; Foster, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 46 KB

6 ALL ORAL THERAPY WITH SOFOSBUVIR + RIB

6 ALL ORAL THERAPY WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT EXPERIENCED GT2/3 HCV-INFECTED PATIENTS: RESULTS OF THE PHASE 3 FUSION TRIAL

✍ Nelson, D.R.; Feld, J.; Kowdley, K.V.; Al-Assi, M.T.; Lin, M.; Mo, H.; McNally, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 74 KB